Authors

Latest:

Dr. Dimou on Managing Disease Progression in NSCLC

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

and Anas Younes, MD, MSKÂ

Anders Mellemgaard, MD, Herlev University Hospital

Anders Neijber, MD, PhD, MBA

Latest:

Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate Cancer

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

AndrÃ© P. Fay, MD

Latest:

Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBC

A review by AndrÃ© P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.

Andre Goy, MD, John Theurer Cancer Center

Latest:

Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCL

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, Hackensack University Medical Center

Andre Goy, MD, MS

Latest:

Progress in Immunotherapy and Precision Medicine: Key Insights from JTCC at ASH 2024

Andre Goy, MD, discusses how progress in immunotherapy and precision medicine at ASH 2024 is shaping the future of cancer treatment, with key insights from the JTCC highlighting emerging therapies and their potential to improve patient outcomes through personalized approaches.

Andre Goy, MD, MS, John Theurer Cancer Center

Andre Goy, MD, MS, John Theurer Cancer Center - Hackensack University Medical Center

Andre H. Goy, MD

Latest:

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

Andre H. Goy, MD, MS

Latest:

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Andrea Apolo, MD

Latest:

Dr Apolo on Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.

Andrea B. Apolo, MD, National Cancer Institute

Latest:

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

Andrea Cercek, MD

Latest:

Novel Therapies in HER2-Amplified Metastatic Colorectal Cancer

Dr Andrea Cercek reviews key clinical trials in HER2-amplified colorectal cancer treatment and considers how the approval of new therapies will impact the current treatment landscape.

Andrea Cercek, MD, Memorial Sloan Kettering Cancer Center

Andrea De Censi, MD

Latest:

Dr. De Censi on the Hope for Biosimilars in the United States

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.

Andrea Merrill, MD

Latest:

Patients Are a Virtue

It is 4:45 am on a Saturday in June.

Andrea Necchi, MD

Latest:

Dr Necchi on Responses With TAR-200 According to PD-L1 Status in NMIBC

Andrea Necchi, MD, discusses treatment with TAR-200 by PD-L1 expression in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer with CIS.

Andrea Price, APN

Latest:

Adding CAR T-Cell Therapy to the Electronic Medical Record

Andrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.